PPRT 424
Latest Information Update: 20 Feb 2008
Price :
$50 *
At a glance
- Originator PharmaPrint
- Class Neuroprotectants; Nootropics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders
Most Recent Events
- 25 Jun 2001 This compound is still in active development
- 10 Dec 1998 New profile
- 10 Dec 1998 Preclinical development for Cognition disorders in USA (Unknown route)